Pre-made Cudarolimab benchmark antibody ( Whole mAb, anti-TNFRSF4/CD134 therapeutic antibody, Anti-ACT35/IMD16/OX40/TXGP1L Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-126
Pre-Made Cudarolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cudarolimab (formerly IBI 101) is a recombinant fully human anti-OX40 (tumour necrosis factor receptor superfamily member 4) monoclonal antibody, being developed by Innovent Biologics, for the treatment of various cancers, including solid tumours, and hepatitis B.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Cudarolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Solid tumours|